A World Health Organization (WHO) report has discovered no adverse health results but instead a few medicinal applications for cannabidiol (CBD), despite U.S. government policy on this cannabinoid substance.
According to the WHO report* (1) CBD is safe and well tolerated by humans and animals and it isn’t related to any negative health effects. Expert stated that the non-psychoactive chemical found in cannabis (CBD) does not induce physical dependence and is "not associated with abuse potential." The WHO research team also wrote that, unlike THC, people aren't getting high because of CBD.
The WHO report also sustains that “To date, there is no evidence of recreational use of CBD or any public health related problems associated with the use of pure CBD.”
In the WHO report is wrote that CBD has "been demonstrated as an effective solution for epilepsy" in adults, children, and even animals and that there's also "preliminary evidence" that CBD can help in dealing with Alzheimer’s disease, cancer, psychosis, Parkinson's disease, and other serious conditions.
Because of the studies that were made in recent years, the report mentioned also that "Several countries have modified their national controls to accommodate CBD as a medicinal product."
Unfortunately, the U.S., as the report noted, isn't one of them. As a cannabis segment, CBD stays named a Schedule I controlled substance, which means it has a "high potential for abuse" in the federal government's view. Nevertheless, the "unsanctioned medical use" of CBD is genuinely normal as specialists found.
For some CBD clients in the U.S., the substance's mostly unsanctioned and illegal state creates issues, particularly as a wave of on the online (mostly hemp) and locally acquired CBD oils and extracts have enabled patients to take the procedure - and the risks associated with purchasing unregulated pharmaceutical - into their own hands and homes. While CBD itself is safe and observed to be useful for some clients, industry specialists have cautioned that not all cannabis extracts are made equally, purely, or with similar techniques for extraction.
In September, NORML (cannabis reform non-profit) submitted written testimony to the U.S. Food and Drug Administration (FDA) contradicting the establishment of international restrictions on access to CBD. The FDA, which has repeatedly declined to update its position on cannabis products despite an extensive and regularly developing assortment of proof regarding the subject, is one of the various organizations that will advise the WHO in its final review of CBD and maybe, this time the FDA will listen and learn something.
* The report was presented by the WHO's Expert Committee on Drug Dependence, and drafted under the responsibility of the WHO Secretariat, Department of Essential Medicines and Health Products, Teams of Innovation, Access and Use and Policy, Governance, and Knowledge.
This article was written by an independent and third-party author specialising in CBD, hemp and cannabis research. Any opinion, advice or recommendation expressed in the article does not reflect the opinion of Formula Swiss AG or any of our employees. We do not make any claims about any of our products and refer to our disclaimer for more information.
Comments will be approved before showing up.